EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A framework to identify high-priority legacy active pharmaceutical ingredients for environmental risk assessment

Cristiana Cannata iD, Erika Colombo, Ashenafi Legehar iD, Irene Bramke, Annika Buck, Anja Coors, Melvin Faber, Gemma Janer, Samuel K Maynard iD, Rhys Whomsley, Caterina Zillien, Caroline T A Moermond iD und 1 weitere

Integrated Environmental Assessment and Management · 01.11.2026 · 22 (6) · 2047-2058

DOI: 10.1093/inteam/vjag069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Integrated Environmental Assessment and Management, online erschienen am 04.05.2026. Verfasst von Cristiana Cannata und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental Science, Radboud Institute for Biological and Environmental Sciences (RIBES), Radboud University, Nijmegen, The Netherlan…. Hauptthemen laut MEDLINE: Water Pollutants, Chemical, Environmental Monitoring. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prioritisation and Risk Evaluation of Medicines in the EnviRonment, Innovative Medicines Initiative 2 Joint Undertaking, European Union's Horizon 2020 Research and Innovation Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Active pharmaceutical ingredients (APIs) from human medicinal products are detected in surface waters globally, but the extent of their impact remains insufficiently understood. Conducting environmental risk assessments (ERAs), including experimental studies for all pharmaceuticals, is unfeasible, particularly for legacy APIs approved before the ERA became a mandatory requirement in the European Union (EU). This challenge can be addressed by prioritizing legacy APIs for ERA, as highlighted by the European Commission’s recent proposal for revised EU pharmaceutical legislation, calling for scientific criteria to prioritize legacy APIs, using a risk-based approach. In line with this, we present a risk-based prioritization framework to identify high-priority legacy APIs for further testing and ERA. The framework, which is intended as a screening and prioritization tool and not as a substitute for regulatory-compliant ERAs, was applied to a dataset of 1,687 APIs. Environmental concentrations in surface waters were estimated using European volume sales data from 2019 to 2023. Effect concentrations were predicted using multiple approaches, including Quantitative Structure–Activity Relationship (QSAR) models and theoretical therapeutic water concentrations (TWCs). By comparing predicted values against empirical ecotoxicity data, we showed that QSAR models, which generally show acceptable statistical performance, tend to underestimate the effects of highly toxic pharmaceuticals. In contrast, TWC values were more conservative but exhibited greater variability in performance. Exposure and effect concentrations were combined into preliminary risk quotients (pRQs), which were ranked and subsequently benchmarked against a reference ranking for validation. In the final step, multiple pRQs were combined into a single risk-based ranking. This list, along with a summary of ERA data availability for the included APIs, serves as a starting point for stakeholders, such as industry and regulators, to screen legacy APIs for data gaps, guiding decisions on which substances require further ERA, possibly involving testing, and what types of studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Water Pollutants, ChemicalEnvironmental MonitoringRisk AssessmentBulk DrugsEuropean UnionPharmaceutical PreparationsQuantitative Structure-Activity Relationship

Stichwörter der Autor:innen

environmental risk assessmentin silicopharmaceuticalsprioritization

Substanzen

Water Pollutants, ChemicalBulk DrugsPharmaceutical Preparations

Autor:innen und Institutionen

  • Department of Environmental Science, Radboud Institute for Biological and Environmental Sciences (RIBES), Radboud University, Nijmegen, The Netherlands.
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
  • Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Global Sustainability, AstraZeneca, Den Haag, The Netherlands.
  • Translational Sciences Office, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
  • ECT Oekotoxikologie GmbH, Flörsheim/Main, Germany.

ORCID-Profile: Cristiana Cannata, Ashenafi Legehar, Samuel K Maynard, Caroline T A Moermond, Ad M J Ragas

Förderung

  • Prioritisation and Risk Evaluation of Medicines in the EnviRonment
  • Innovative Medicines Initiative 2 Joint Undertaking
  • European Union's Horizon 2020 Research and Innovation Programme
  • European Federation of Pharmaceutical Industries and Associations
  • European Union’s Horizon 2020 Research and Innovation Programme

Zitieren

APA

Cannata, C., Colombo, E., Legehar, A., Bramke, I., Buck, A., Coors, A., Faber, M., Janer, G., Maynard, S. K., Whomsley, R., Zillien, C., Moermond, C. T. A., & Ragas, A. M. J. (2026). A framework to identify high-priority legacy active pharmaceutical ingredients for environmental risk assessment. Integrated Environmental Assessment and Management, 22(6), 2047-2058. https://doi.org/10.1093/inteam/vjag069

Vancouver

Cannata C, Colombo E, Legehar A, Bramke I, Buck A, Coors A, et al. A framework to identify high-priority legacy active pharmaceutical ingredients for environmental risk assessment. Integrated Environmental Assessment and Management. 2026;22(6):2047-2058. doi:10.1093/inteam/vjag069

BibTeX
@article{Cannata2026,
  author = {Cannata, Cristiana and Colombo, Erika and Legehar, Ashenafi and Bramke, Irene and Buck, Annika and Coors, Anja and Faber, Melvin and Janer, Gemma and Maynard, Samuel K and Whomsley, Rhys and Zillien, Caterina and Moermond, Caroline T A and Ragas, Ad M J},
  title = {A framework to identify high-priority legacy active pharmaceutical ingredients for environmental risk assessment},
  journal = {Integrated Environmental Assessment and Management},
  year = {2026},
  volume = {22},
  number = {6},
  pages = {2047--2058},
  doi = {10.1093/inteam/vjag069}
}
Kostenlos starten →